Data as of Nov 21
| +0.04 / +0.62%|
The 8 analysts offering 12-month price forecasts for Endocyte Inc have a median target of 9.50, with a high estimate of 21.00 and a low estimate of 6.00. The median estimate represents a +46.83% increase from the last price of 6.47.
The current consensus among 10 polled investment analysts is to Buy stock in Endocyte Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.